Immunome (IMNM) Assets Average (2020 - 2026)

Immunome's Assets Average history runs 7 years deep, the most recent figure standing at $651.5 million for Q1 2026.

• Quarterly Assets Average rose 123.52% year-over-year to $651.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651.5 million (up 123.52% YoY) and the FY2025 annual result came in at $461.7 million, up 137.52% from the prior year.
• Assets Average was $651.5 million for Q1 2026 at Immunome, up from $491.3 million in the prior quarter.
• Across five years, Assets Average topped out at $651.5 million in Q1 2026 and bottomed at $27.3 million in Q4 2022.
• A 5-year average of $208.6 million and a median of $234.1 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average plunged 54.69% — and 2024, when it jumped 587.86%.
• Immunome's Assets Average stood at $27.3 million in 2022, then surged by 342.74% to $120.9 million in 2023, then soared by 105.68% to $248.6 million in 2024, then soared by 97.64% to $491.3 million in 2025, then jumped by 32.61% to $651.5 million in 2026.
• Business Quant data shows IMNM's Assets Average at $651.5 million in Q1 2026, $491.3 million in Q4 2025, and $297.8 million in Q3 2025.